Skip to main content

Table 1 The baseline characteristics in the nafamostat mesilate and the control groups

From: The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis

  Nafmostat mesilate (n = 201) Control (n = 149) Total (N = 350) P value
Age, y, median (range) 68 (55–75) 66 (54–74) 66 (55–75) 0.436
Male (%) 74 (36.8) 59 (39.6) 133 (38.0%) 0.596
History of AP (%) 3 (1.5) 0 3 (0.9%)  
SOD (%) 2 (1.0) 0 2 (0.6%)  
Purpose of ERCP (%)
 Choledocholithiasis 120 (59.7) 81 (54.4) 201 (57.4%) 0.318
 Malignant biliary stricture 67 (33.3) 56 (37.6) 123 (35.1%) 0.410
 Benign biliary stricture 11 (5.5) 8 (5.4) 19 (5.4%) 0.966
 Biliary leakage 0 1 (0.7) 1 (0.3%)  
 Pancreatic cyst 1 (0.5) 2 (1.3) 3 (0.9%) 0.577
 Other indicationa 2 (1.0)* 1 (0.7) 3 (0.9%) 0.745
Procedures (%)
 Difficult cannulation 115 (57.2) 59 (39.6) 174 (49.7%) 0.001
 P-duct manipulation 69 (34.3) 44 (29.5) 113 (32.3%) 0.342
 Precut EST 70 (34.8) 42 (28.2) 112 (32.0%) 0.188
 Pancreatic EST 44 (21.9) 20 (13.4) 64 (18.3%) 0.043
 EPBD 21 (10.4%) 18 (12.1%) 39 (11.1%) 0.631
 ERPD 43 (21.4%) 20 (13.4%) 63 (18.0%) 0.055
  1. AP acute pancreatitis, SOD sphincter of Oddi dysfunction, ERCP endoscopic retrograde cholangiopancreatography, P-duct pancreatic duct, EST endoscopic sphincterotomy, EPBD endoscopic papillary balloon dilatation, ERPD endoscopic retrograde pancreatic drainage
  2. aIntraductal papillary neoplasm of bile duct, Mirrizi’s syndrome